Global Antibiotics Market, By Indication (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections and Others), Drug Class (Beta Lactam and Beta Lactamase Inhibitors, Quinolone, Macrolide, Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic, Narrow-spectrum Antibiotic), Route of Administration (Oral, Parenteral, Topical, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy Others)- Industry Trends and Forecast to 2029.
Market Analysis and Insights
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria.
- The antibiotics is supportive and aims to destroying bacteria and curing infections. Data Bridge Market Research analyses that the antibiotics market will grow at a CAGR of 5.16% during the forecast period of 2022 to 2029. “Hospital” segment dominates the end user market.
Antibiotics Market Dynamics
Increasing number of patients suffering from infectious diseases
Infections are major problem in healthcare system and with cOVID-19 is showing rise in the number of people with infection and diseases act as a major driver that will result in the expansion of the growth rate of the treatment market.
Advances in antibiotics drugs
Also, the pharmaceuticals companies are making much progress in the advancement of these drugs antibiotic is making much advancement than generic medicine and it will further enhance the growth of antibiotics market.
Furthermore, novel combination therapies to treat antibiotic-resistant microbial infections can advance the treatment landscape and a special designation from the regulatory authority to various potential pharmaceuticals companies and ongoing clinical trials are being conducted by many pharmaceuticals companies will result in the expansion of antibiotics market.
Surge volume of patients suffering from infectious diseases and development in newer diagnostics devices
However, antibiotic resistance and lengthy and tedious regulatory procedures will impede the growth rate of antibiotics market. The side effects of antibiotics and self-medication will further challenge the market in the forecast period mentioned above.
This antibiotics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on antibiotics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to the United Nation's Ageing Population Report 2019, the global population aged 60 years or over was numbered at 962 million in 2017, more than twice as large as in 1980 when there were 382 million older persons worldwide. In 2018, 447,694 diagnoses of sexually transmitted infections (STIs) were made in the United Kingdom, a 5% increase compared to 2017. Additionally, 56,259 diagnoses of gonorrhea were reported in 2018, a 26% increase compared to 2017, and 7,541 diagnoses of syphilis were reported in 2018, a 5% increase compared to 2017
According to the WHO, in 2019, 10 million people were suffering from tuberculosis (TB) globally, and 1.4 million people died due to the disease.
Antibiotics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Antibiotics Market
In addition, with the high need for the development of drugs and treatment for COVID-19, antibiotics are extensively being studied. For instance, in March 2020, Pfizer announced positive data for the use of its azithromycin (Zithromax) drug, along with hydroxychloroquine, in a coronavirus (COVID-19) clinical trial performed in France. Similarly, according to a study of 368 patients, in April 2020, there was no significant difference in mechanical ventilation risks in three cohorts of patients treated with hydroxychloroquine alone, a combo of hydroxychloroquine and azithromycin, and supportive care alone.
- In October 2020, Pfizer Inc. announced the acquisition of Arixa Pharmaceuticals Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections.
Global Antibiotics Market Scope
The antibiotics market is segmented on the basis of indication, drug class, and drug origin, spectrum of activity, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Urinary tract infection
- Intra-abdominal infections
- Blood stream infections
- Clostridium difficile infections
On the basis of indication, the antibiotics market is segmented into urinary tract infection, intra-abdominal infections, blood stream infections, clostridium difficile infections and others.
- Beta lactam
- Beta lactamase
The drug class segment for antibiotics market includes beta lactam & beta lactamase inhibitors, quinolone, macrolide and others.
On the basis of drug origin, the antibiotics market is segmented into natural, semisynthetic, synthetic.
Spectrum of activity
- Broad-spectrum antibiotic
- Narrow-spectrum antibiotic
Antibiotics market is segmented into broad-spectrum antibiotic and narrow-spectrum antibiotic on the basis of spectrum of activity.
Route of Administration
Route of administration segment of antibiotics market is segmented into oral, parenteral, topical and others.
- Specialty Clinic
On the basis of end-users, the antibiotics market is segmented into hospitals, homecare, specialty clinics and others.
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Antibiotics market has also been segmented based on the distribution channel into hospital pharmacy, online pharmacy, retail pharmacy others.
In September 2020, Shionogi launched its new gram-negative antibiotic Fetcroja in the United Kingdom, which protects against all Gram-negative pathogens. In January 2020, Wockhardt received regulatory approval for its new antibiotics, EMROK (IV) and EMROK O (Oral), for the indication of acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. The U.S. FDA granted Fast Track designations, Qualified Infectious Disease Product (QIDP) designation, and marketing exclusivity till 2028 for the product.
Antibiotics Market Regional Analysis/Insights
The antibiotics market is analysed and market size insights and trends are provided by country, indication, drug class, and drug origin, spectrum of activity, route of administration, end-users and distribution channel as referenced above.
The countries covered in the antibiotics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific dominates the antibiotics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to larger population, high prevalence cases of infectious disease and lenient regulation on antibiotics drugs in this region. North America on the other hand is projected to exhibit the highest growth rate during the forecast period due to the focus of various established market players to expand their presence in this particular region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Antibiotics Market Share Analysis
The antibiotics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antibiotics market.
Some of the major players operating in the antibiotics market are Johnson & Johnson Services, Inc, Sanofi, Bayer AG, Abbott, F. Hoffmann-La Roche Ltd, Melinta Therapeutics, INC, Merck & Co., Inc., Allergan, Pfizer Inc, Novartis AG, LG Chem, Mylan N.V, Lupin, Hitech, Amneal Pharmaceuticals LLC, Zydus Cadila, Bausch Health, Teva Pharmaceutical Industries Ltd, Akron Incorporated, KYORIN Holdings, Inc, MerLion Pharmaceuticals GmbH and Wockhardt among others.